Gemmer Asset Management LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 16.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 39,315 shares of the biopharmaceutical company’s stock after purchasing an additional 5,490 shares during the period. Gemmer Asset Management LLC’s holdings in Pfizer were worth $1,424,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Janus Henderson Group PLC increased its stake in shares of Pfizer by 243.5% during the second quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock worth $442,574,000 after purchasing an additional 9,339,749 shares during the period. Vanguard Group Inc. increased its stake in shares of Pfizer by 2.3% during the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after purchasing an additional 9,239,499 shares during the period. Renaissance Technologies LLC bought a new position in shares of Pfizer during the second quarter worth approximately $268,389,000. Stifel Financial Corp increased its stake in shares of Pfizer by 5,413.5% during the third quarter. Stifel Financial Corp now owns 7,360,192 shares of the biopharmaceutical company’s stock worth $262,515,000 after purchasing an additional 7,226,697 shares during the period. Finally, Longview Partners Guernsey LTD increased its stake in shares of Pfizer by 32.0% during the third quarter. Longview Partners Guernsey LTD now owns 24,369,672 shares of the biopharmaceutical company’s stock worth $869,997,000 after purchasing an additional 5,901,100 shares during the period. 71.41% of the stock is owned by hedge funds and other institutional investors.
In related news, insider Charles H. Hill sold 42,393 shares of the firm’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $35.76, for a total transaction of $1,515,973.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Rady A. Johnson sold 8,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the transaction, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 185,464 shares of company stock valued at $6,767,939. 0.06% of the stock is owned by corporate insiders.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The business had revenue of $13.70 billion during the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. Pfizer’s revenue for the quarter was up .6% compared to the same quarter last year. During the same period last year, the company earned $0.47 EPS. research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer declared that its board has authorized a stock buyback program on Monday, December 18th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its stock is undervalued.
The business also recently announced a quarterly dividend, which was paid on Thursday, March 1st. Investors of record on Friday, February 2nd were given a dividend of $0.34 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a yield of 3.70%. The ex-dividend date was Thursday, February 1st. Pfizer’s dividend payout ratio (DPR) is currently 77.71%.
A number of equities analysts have recently weighed in on the company. BMO Capital Markets set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, March 6th. Jefferies Group set a $39.00 price target on Pfizer and gave the stock a “hold” rating in a research report on Monday, February 26th. Berenberg Bank set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, January 30th. UBS Group set a $42.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Finally, Leerink Swann increased their price target on Pfizer from $35.00 to $38.00 and gave the stock a “market perform” rating in a research report on Wednesday, January 31st. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $39.40.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.